學名藥市場規模、佔有率、成長分析（按給藥途徑、按治療用途、按劑型、按分銷管道、按最終用戶、按地區）－2025-2032 年產業預測

2023 年全球學名藥市場規模價值 4,872.1 億美元，預計將從 2024 年的 5,130.3 億美元成長到 2032 年的 7,754.8 億美元，預測期內（2025-2032 年）的複合年成長率為 5.3%。

受慢性病發病率上升和對具有成本效益的藥物選擇的需求推動，學名藥市場正在經歷顯著成長。學名藥（ 學名藥 ）具有與品牌藥相同的化學成分，但價格較低，在新興經濟體和已開發經濟體中越來越受歡迎。 FDA 專利保護為品牌藥物開發商提供了暫時的獨佔權，以防止學名藥競爭。然而，一旦專利到期，學名藥可以透過快速核准程序迅速進入市場，同時遵守嚴格的品質、安全和功效標準。高價值藥物專利到期進一步推動了這一趨勢，促進了學名藥的開發和供應，從而支持了市場擴張。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 監管格局
• 客戶和購買標準分析

學名藥市場規模（按給藥途徑和複合年成長率） (2025-2032)

• 市場概覽
• 口服
• 腸外
• 局部的
• 吸入
• 經皮
• 眼科
• 其他

學名藥市場規模（依治療用途和複合年成長率） (2025-2032)

• 市場概覽
• 心血管疾病
• 中樞神經系統 (CNS) 疾病
• 感染疾病
• 腫瘤學
• 呼吸系統疾病
• 胃腸道疾病
• 內分泌失調
• 其他

學名藥市場規模（按劑型分類）及複合年成長率（2025-2032）

• 市場概覽
• 固態劑型
• 液體劑型
• 半固態形式
• 氣體形式

學名藥市場規模（依分銷管道分類）及複合年成長率（2025-2032）

• 市場概覽
• 醫院藥房
• 零售藥局
• 網路藥局
• 藥局
• 批發商和經銷商

學名藥市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概覽
• 醫院
• 診所
• 居家照護環境
• 門診手術中心（ASC）
• 零售消費者

學名藥市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Sandoz-Switzerland
• Teva Pharmaceuticals-Israel
• Sun Pharmaceutical Industries Ltd.-India
• Viatris Inc.-USA
• Fresenius Kabi AG-Germany
• Cipla Ltd.-India
• Dr. Reddy's Laboratories Ltd.-India
• Lupin Limited-India
• Aspen Pharmacare Holdings Limited-South Africa
• Zydus Cadila-India
• KRKA dd-Slovenia
• Towa Pharmaceutical Co., Ltd.-Japan
• STADA Arzneimittel AG-Germany
• Glenmark Pharmaceuticals Ltd.-India
• Amneal Pharmaceuticals, Inc.-USA
• Biocon Limited-India
• Aurobindo Pharma Ltd.-India
• Sawai Pharmaceutical Co., Ltd.-Japan
• Torrent Pharmaceuticals Ltd.-India
• Hikma Pharmaceuticals PLC-UK

結論和建議

Global Generic Drugs Market size was valued at USD 487.21 billion in 2023 and is poised to grow from USD 513.03 billion in 2024 to USD 775.48 billion by 2032, growing at a CAGR of 5.3% during the forecast period (2025-2032).

The generic drug market is experiencing significant growth, driven by the rising prevalence of chronic diseases and the demand for cost-effective medication options. Generic drugs, which share the same chemical composition as their branded counterparts but are available at lower prices, are gaining traction in both developing and developed economies. The patent protection granted by the FDA gives branded drug developers a temporary monopoly, preventing generic competition. However, once patents expire, generic drugs can swiftly enter the market through expedited approval processes while adhering to stringent quality, safety, and efficiency standards. This trend is further fueled by the expiration of patents for high-value medications, leading to an increase in the development and accessibility of generic alternatives, bolstering market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Generic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Generic Drugs Market Segments Analysis

Global Generic Drugs Market is segmented by Route of Administration, Therapeutic Application, Formulation, Distribution Channel, End User and region. Based on Route of Administration, the market is segmented into Oral, Parenteral, Topical, Inhalation, Transdermal, Ophthalmic and Others. Based on Therapeutic Application, the market is segmented into Cardiovascular Disorders, Central Nervous System (CNS) Disorders, Infectious Diseases, Oncology, Respiratory Diseases, Gastrointestinal Disorders, Endocrine Disorders and Others. Based on Formulation, the market is segmented into Solid Dosage Forms, Liquid Dosage Forms, Semi-solid Forms and Gaseous Forms. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores and Wholesalers & Distributors. Based on End User, the market is segmented into Hospitals, Clinics, Homecare Settings, Ambulatory Surgical Centers (ASCs) and Retail Consumers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Generic Drugs Market

The Global Generic Drugs market is significantly driven by the rising prevalence of chronic illnesses, which continues to escalate with the growing aging population. As recorded in 2021, there were over 10.1 million cancer cases in men and 9.3 million in women, alongside more than 350 million individuals diagnosed with arthritis worldwide. This increasing burden of chronic diseases necessitates improved health services, thereby fueling the demand for affordable and accessible healthcare solutions. Consequently, the generic drugs market is anticipated to experience substantial growth throughout the forecast period, as healthcare systems strive to meet the evolving needs of patients.

Restraints in the Global Generic Drugs Market

A significant obstacle hindering the expansion of the global generic drugs market is the stringent regulatory framework imposed by authorities such as the FDA. This agency meticulously assesses the accuracy, potential side effects, and compositional integrity of generic medications. Should manufacturers fail to adhere to these strict standards, they are compelled to withdraw their products from the market. Consequently, the necessity for regulatory approval for generic pharmaceuticals can create delays and complications, ultimately impacting market growth projections. This regulatory environment poses a challenge for manufacturers striving to introduce new generic drugs, thus limiting the overall development of the sector.

Market Trends of the Global Generic Drugs Market

The Global Generic Drugs market is witnessing significant growth, driven by the robust production and consumption of generics in India, which ranks as the third largest pharmaceutical market by volume and fourteenth by value. With over 3,000 pharmaceutical companies and more than 10,500 factories, India is a key player, offering a diverse range of generic drugs. The country is recognized for having the highest number of US-FDA approved manufacturing plants outside the United States, further bolstering its global position. This trend indicates a growing reliance on affordable medications, positioning India as a pivotal hub in the global pharmaceuticals landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Customer & Buying Criteria Analysis

Global Generic Drugs Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral
• Topical
• Inhalation
• Transdermal
• Ophthalmic
• Others

Global Generic Drugs Market Size by Therapeutic Application & CAGR (2025-2032)

• Market Overview
• Cardiovascular Disorders
• Central Nervous System (CNS) Disorders
• Infectious Diseases
• Oncology
• Respiratory Diseases
• Gastrointestinal Disorders
• Endocrine Disorders
• Others

Global Generic Drugs Market Size by Formulation & CAGR (2025-2032)

• Market Overview
• Solid Dosage Forms
• Liquid Dosage Forms
• Semi-solid Forms
• Gaseous Forms

Global Generic Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• Wholesalers & Distributors

Global Generic Drugs Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Homecare Settings
• Ambulatory Surgical Centers (ASCs)
• Retail Consumers

Global Generic Drugs Market Size & CAGR (2025-2032)

• North America (Route of Administration, Therapeutic Application, Formulation, Distribution Channel, End User)
  • US
  • Canada
• Europe (Route of Administration, Therapeutic Application, Formulation, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Route of Administration, Therapeutic Application, Formulation, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Route of Administration, Therapeutic Application, Formulation, Distribution Channel, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Route of Administration, Therapeutic Application, Formulation, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Sandoz - Switzerland
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceuticals - Israel
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. - India
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. - USA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG - Germany
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. - India
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. - India
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited - India
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aspen Pharmacare Holdings Limited - South Africa
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila - India
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KRKA d.d. - Slovenia
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Towa Pharmaceutical Co., Ltd. - Japan
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• STADA Arzneimittel AG - Germany
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glenmark Pharmaceuticals Ltd. - India
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals, Inc. - USA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Limited - India
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Ltd. - India
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sawai Pharmaceutical Co., Ltd. - Japan
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd. - India
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC - UK
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations